Sexually transmitted infections in the United States consume a reported $16 billion in medical costs each year, with 20 million new infections reported annually1. In 2014, there were over 1.4 million new chlamydial infections in the United States1. Delays in treatment for C. trachomatis infections in women have been associated with Pelvic Inflammatory Disease, ectopic pregnancy, and infertility. Gonorrhea is the second most commonly reported communicable disease, with 800,000 cases reported in the US in 20081. T. vaginalis is a parasite that is often associated with symptoms of vaginitis and is the causative agent of Trichomoniasis. While Trichomoniasis is associated with pregnancy complications, infertility, and increased transmission of HIV, as many as 85% of women testing positive for T. vaginalis report no symptoms.
As a result of poor sensitivity of conventional methods, the CDC now recommends molecular assays for diagnosis of C. trachomatis, N. gonorrhoeae, and T. vaginalis.2
Prompt detection and treatment are necessary to prevent further transmission of these common infections, with the time-to-result particularly critical for high-risk patients that may not return to the clinic or hospital for follow-up diagnosis and treatment.
Great Basin is developing a sample-to-result molecular diagnostic assay that simultaneously detects C. trachomatis, N. gonorrhoeae, and T. vaginalis directly from swab media or urine specimens. This assay will feature unparalleled ease-of-use and an actionable time-to-result.
For more information on our system or to schedule a demo, please contact Great Basin Sales.
1MMWR Sexually Transmitted Diseases Treatment Guidelines, 2015, http://www.cdc.gov/std/tg2015/tg-2015-print.pdf
2MMWR Recommendations for the Laboratory-based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae-2014, http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6302a1.htm